The formulary is a device list
From 1 July 2026 through 31 December 2027 the Bridge drugs are Wegovy (pen and pill), Foundayo, and Zepbound KwikPen. 'Zepbound' in conversation is not specific enough. The demonstration names a presentation.
A PA written for a non-KwikPen Zepbound NDC is a PA written for a product the demonstration does not stock.
Pharmacy and chart have to say the same word
Call the pharmacy that will dispense and ask which Zepbound NDC they order for Bridge. Put that NDC and the word KwikPen on the clinician checklist.
If the clinic's usual sample or training device is a different injector, that habit does not move CMS. Train on the covered presentation or pick a different Bridge drug.
Commercial and cash are separate shelves
A commercial plan may cover a different Zepbound device than Bridge does. Manufacturer cash via LillyDirect may also show more than one presentation. Those shelves do not expand the Medicare demonstration.
Government beneficiaries still cannot use the commercial savings card, regardless of device.
When Zepbound is the wrong path entirely
If the prescription is for type 2 diabetes, the labeled tirzepatide diabetes product and Part D rules apply — not Bridge. Moderate-to-severe OSA may be a covered Part D indication for Zepbound depending on the plan and the chart; that is still not an invitation to file Bridge to 'get $50.'
Someone already filling a 2026 Part D GLP-1 is generally Bridge-ineligible even if their device happens to be a KwikPen.
2027
When the demonstration ends on 31 December 2027, KwikPen status on Bridge dies with it. Open enrollment is when you read the 2027 (and later the 2028) formulary for whatever device the plan actually lists.
Questions
Can the pharmacist substitute another Zepbound pen?
Does KwikPen change the $50?
Is Wegovy similarly device-limited?
What should the adult child tell the clinic?
Not sure this applies to you?
Answer a few questions and see your own numbers.
Free to see which path is likely cheapest for your coverage.
Check my options